Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting - Seite 2

Location: Exhibit Hall‚ ePoster Hub

Title: A Phase 3, Multicenter, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: October 7, 2023
Session Title: ePoster Viewing Sessions - ePoster Viewing Session III
Session Time: 1:00 – 2:30 PM ET
Poster Number: CTC-005
Presentation Time: 2:00 – 2:30 PM ET
Location: Exhibit Hall‚ ePoster Hub

Title: A Phase 3 Randomized Controlled Trial Comparing Aficamten vs Metoprolol in Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Presenter: Michael A. Fifer, MD, Director of Hypertrophic Cardiomyopathy Program at Massachusetts General Hospital Heart Center
Date: October 7, 2023
Session Title: ePoster Viewing Sessions - ePoster Viewing Session IV
Poster Number: CTC-006
Session Time: 4:45 – 5:45 PM ET
Presentation Time: 4:45 – 5:15 PM ET
Location: Exhibit Hall‚ ePoster Hub

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Aficamten is a next-in-class cardiac myosin inhibitor, currently the subject of three Phase 3 clinical trials: SEQUOIA-HCM, evaluating aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), MAPLE-HCM, evaluating aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM and ACACIA-HCM, evaluating aficamten in patients with non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator in patients with heart failure. Additionally, Cytokinetics is developing CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility, and CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF. In 2023, Cytokinetics is celebrating its 25-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.